

REMARKS


Applicants respectfully request entry of this Supplemental Amendment. Apart from the amendment of Claim 30, Applicants request consideration of the following points of clarification in the argument portion of the Amendment and Response filed on December 23, 2002. Page 5, paragraph 8, line 5 should read "demonstrate the." Page 8, second paragraph, line 7 should read "clones." In addition, on page 9, Applicants discuss Dickson et al. For clarification, Applicants state that Dickson et al. does not disclose which antigen should be used to obtain a monoclonal antibody with the characteristics of the monoclonal antibodies of the claimed invention.

Finally, in the Examiner's Office Action mailed on June 26, 2002, the Examiner requested identification of applications and patents issued involving tau monoclonal antibodies. U.S. Patent No. 6,121,003 is the only issued patent not previously indicated by the Examiner.

Respectfully submitted,

MERCHANT & GOULD P.C.
P. O. Box 2903
Minneapolis, Minnesota 55402-0903
612.332.5300

Date 1-13-03


Rebecca A. Bortolotti
Reg. No. 51,488
RAB:rlr



Serial No. 09/734,281

VERSION WITH MARKINGS TO SHOW CHANGES MADE

in the Claims

Claim 30 has been amended as follows:

30. A monoclonal antibody according to claim 20, wherein said monoclonal antibody forms an immunological complex with an epitope of the human abnormally [serines present in the human abnormally] phosphorylated tau protein comprising a phosphorylated serine[s].